• Investors
  • News
  • Contact
Iconovo
  • About us
    • Board of Directors
    • Management
    • Our Team
    • Sustainability
    • Career
    • Investors
  • Inhalers
    • Inhalers
    • ICOres
    • ICOcap
    • ICOpre
    • ICOone
    • ICOone Nasal
    • Patents
  • Development capabilities
    • Development capabilities
    • Inhalers
    • Formulation
    • Pharmaceutical Analysis
    • Advisory services
  • Partner with us
    • Partner with us
    • Access our inhalers
  • Insights
    • Systemic Delivery of Biologics via Inhalation
    • Replacing injections with inhalation
    • Boost your business with an innovative inhaler partner
  • Investors
  • Search
  • Menu Menu
  • LinkedIn

Quarterly Report for Q1 2022 released

April 29, 2022/in News /by Eva Norell

The Quarterly Report for Q1 2022 was released today and is available here, in Swedish.

Share this entry
  • Share on Twitter
  • Share on LinkedIn
  • Share by Mail
https://www.iconovo.se/wp-content/uploads/2022/06/Nyhetsbilder-.jpg 900 1600 Eva Norell https://www.iconovo.se/wp-content/uploads/2021/03/Breathtaking-innovation_Iconovo.png Eva Norell2022-04-29 14:59:482022-06-13 16:08:38Quarterly Report for Q1 2022 released

Possessing a unique combination

of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.

ICONOVO AB

VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B

POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden

CONTACT

Phone: +46 46 275 67 77

VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se

CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se

SITEMAP

  • Home
  • Development capabilities
  • Investors

Press releases

Subscribe

Follow us on Linkedin

Annual Report 2021 released Iconovo and Galenica enters a strategic collaboration for the development of...
Scroll to top